Citation

Healy D. Ethical Hum. Psychol. Psychiatry 2005; 7(3): 181-195.

Copyright

(Copyright © 2005, Springer Publishing Company)

DOI

10.1891/1559-4343.7.3.181

PMID

unavailable

Abstract

Against a background of longstanding concerns that antidepressants may trigger suicidality, the Food and Drug Administration (FDA) in 2004 convened two committees to review the issues. Prior to the second meeting Pfizer posted an extensive ad hominem attack on me on FDA's website. There was no opportunity to post a response. This article covers the points made in response and sheds some light on pharmaceutical company handling of debates about adverse events. © 2005 Springer Publishing Company.

Language: en

Keywords

human; Suicide; depression; suicidal behavior; FDA; review; conflict; antidepressant agent; paroxetine; serotonin uptake inhibitor; sertraline; priority journal; publication; drug industry; food and drug administration; Sertraline; Warnings